Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Sabine KürzelAndré-René BlaudszunLilly StahlRegina HerbstFrank KroschinskyJosef BirkmannAnnette HänelKerstin Schaefer-EckartGerhard EhningerFriedrich FiedlerMartin BornhäuserStephan FrickeMathias HänelPublished in: Journal of cancer research and clinical oncology (2021)
7 April 2021, retrospectively registered.